Amphastar Pharmaceuticals, Inc.
HealthcareNASDAQ:AMPH · NASDAQ Global Select
-$0.44 today
Vol 0.38M · Avg 0.59M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$720.5M of revenue converted into $79.2M of net income for the selected period. Gross margin is 47.2% and net margin is 11.0%, showing how much revenue survives after costs and taxes. EPS is $1.66, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $719.9M -1.7% | $732.0M +13.6% | $644.4M +29.1% | $499.0M +14.0% | $437.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $363.8M +1.6% | $358.1M +22.1% | $293.3M +17.3% | $250.1M +5.1% | $238.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $356.1M -4.8% | $373.9M +6.5% | $351.1M +41.1% | $248.9M +24.6% | $199.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 49.5% -1.6pp | 51.1% -3.4pp | 54.5% +4.6pp | 49.9% +4.2pp | 45.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $85.8M +16.1% | $73.9M +0.2% | $73.7M -1.4% | $74.8M +22.7% | $60.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $129.8M +37.3% | $94.5M +17.6% | $80.4M +20.7% | $66.6M -3.4% | $68.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $215.7M +28.0% | $168.4M +9.3% | $154.1M +9.0% | $141.4M +8.9% | $129.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $57.2M +36.9% | $41.8M +47.8% | $28.3M +6.6% | $26.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $149.1M -46.2% | $277.3M +15.4% | $240.3M +64.4% | $146.2M +31.0% | $111.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 20.7% -17.2pp | 37.9% +0.6pp | 37.3% +8.0pp | 29.3% +3.8pp | 25.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $140.4M -31.7% | $205.4M +4.3% | $197.0M +83.2% | $107.5M +53.8% | $69.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 19.5% -8.6pp | 28.1% -2.5pp | 30.6% +9.0pp | 21.5% +5.6pp | 16.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.7M -18.2% | $10.6M +94.4% | $5.5M +313.2% | $1.3M +119.8% | $601.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $25.5M -16.0% | $30.3M +11.7% | $27.2M +1371.2% | $1.8M +108.6% | $885.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$16.8M -3.4% | -$16.2M +41.2% | -$27.6M -474.8% | $7.4M -47.6% | $14.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $123.6M -34.7% | $189.2M +11.7% | $169.4M +47.5% | $114.9M +36.9% | $83.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 17.2% -8.7pp | 25.8% -0.4pp | 26.3% +3.3pp | 23.0% +3.8pp | 19.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $25.5M -14.0% | $29.7M -6.8% | $31.8M +35.6% | $23.5M +13.8% | $20.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | $98.1M -38.5% | $159.5M +16.0% | $137.5M +50.5% | $91.4M +47.1% | $62.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 13.6% -8.2pp | 21.8% +0.4pp | 21.3% +3.0pp | 18.3% +4.1pp | 14.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -36.2% | $3 +15.4% | $3 +51.6% | $2 +44.6% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -33.7% | $3 +17.7% | $3 +49.4% | $2 +39.2% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $46.7M -3.5% | $48.4M +0.3% | $48.3M -0.6% | $48.6M +1.6% | $47.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $48.2M -7.4% | $52.1M -1.8% | $53.0M +1.1% | $52.4M +5.3% | $49.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dynavax Technologies Corporation
DVAX
$1.82B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
CureVac N.V.
CVAC
$1.05B
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Beta Bionics, Inc.
NASDAQ:BBNX
$647.48M
Embecta Corp.
NASDAQ:EMBC
$183.92M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AMPH generate?
Amphastar Pharmaceuticals, Inc. (AMPH) reported $719.89M of revenue in fiscal 2025.
Is AMPH profitable?
Amphastar Pharmaceuticals, Inc. (AMPH) reported $98.09M of net income, with a net margin of 13.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.